Hydroxychloroquine (sulfate)

Hydroxychloroquine (sulfate)

• CAS Number: 747-36-4
• UNSPSC Description: Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
• Target Antigen: Autophagy; Parasite; SARS-CoV; Toll-like Receptor (TLR)
• Type: Reference compound
• Related Pathways: Anti-infection;Autophagy;Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Infection
• Assay Protocol: https://www.medchemexpress.com/Hydroxychloroquine_sulfate.html
• Purity: 99.99
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 110 mg/mL (ultrasonic;warming)
• Smiles: CCN(CCO)CCCC(NC1=CC=NC2=CC(Cl)=CC=C12)C.O=S(O)(O)=O
• Molecular Weight: 433.95
• References & Citations: [1]Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.|[2]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40.|[3]Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: ciaa237.ACS Appl Mater Interfaces. 2022 Oct 27.|Acta Pharm Sin B. 2021 Dec;11(12):3966-3982.|Acta Pharmacol Sin. 2022 Oct 25.|Autophagy. 2022 Oct 27.|Biochem Pharmacol. 2021 Dec 28;114904.|bioRxiv. 2024 Dec 5:2024.12.04.626665.|BMC Med. 2021 Oct 15;19(1):247.|Cell Death Dis. 2020 Apr 24;11(4):279.|Cell Discov. 2020 Mar 18;6:16.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Cell Signal. 2019 Feb;54:17-26. |Clin Chem. 2019 Dec;65(12):1522-1531. |Clin Sci (Lond). 2019 Aug 14;133(15):1759-1777.|Eur J Pharmacol. 2 September 2022, 175237.|Front Bioeng Biotechnol. 2020 May 8;8:378.|Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.|Heliyon. 2023 Oct 31.|iScience. 30 June 2022, 104690.|J Autoimmun. 2019 May;99:39-47.|J Biol Chem. 2023 May 11;104814.|J Control Release. 2020 Jan 28;320:304-313.|Life Sci. 2020 Apr 1;246:117366.|Life Sci. 2020 Feb 15;243:117277.|Life Sci. 2021 Oct 26;120095.|Nat Biomed Eng. 2021 Nov 8.|Nat Commun. 2021 Aug 16;12(1):4964.|Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.|Pharmacol Res. 2021 Apr 30;169:105642.|Phytomedicine. 2021, 153465.|Research Square Preprint. 2021 Oct.|Sci Rep. 2022 Oct 29;12(1):18259.|STAR Protoc. 2022, 3(4): 101859.|Theranostics. 2020 Apr 27;10(13):5829-5844. |ACS Omega. 2024 Feb 28;9(10):11870-11882.|Acta Pharmacol Sin. 2021 Feb 19.|Aging. 2021 Mar 10;13(6):8421-8439.|Am J Cancer Res. 2020 Nov 1;10(11):3896-3910.|Arthritis Rheumatol. 2022 Sep 3.|Autophagy. 2021 Sep 15;1-19.|Autophagy. 2022 Aug 29.|Autophagy. 2022 Jan 6;1-20.|Biochem Biophys Res Commun. 2 March 2022.|Biochem Biophys Res Commun. 2020 Dec 10;533(3):474-480.|Bioorg Chem. 2024 Apr 29:147:107412.|Br J Pharmacol. 2023 Feb 14.|Cell Biochem Funct. 2022 Apr 29.|Curr Med. 2023 Oct 17.|iScience. 30 June 2022, 104690.|J Exp Pharmacol. 2022 Nov 8;14:353-365|J Transl Med. 2024 Aug 22;22(1):785.|Mol Cancer. 2024 Oct 31;23(1):243.|Nat Biotechnol. 2022 Dec;40(12):1834-1844.|Nat Commun. 2022 Jun 14;13(1):3419.|Patent. US20230218606A1.|Patent. US20240238271A1.|Phytomedicine. 2024 Sep 26:135:156059.|Res Sq. 2024 Jun 21.|Research Square Preprint. 2023 Sep 6.|Virology. 2023 Jul 24.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: Launched